Effectiveness and safety of ceftazidime-avibactam in Chinese patients with hospital-acquired pneumonia, including ventilator-associated pneumonia: A Phase 4, multi-centre, open-label study

Background: Ceftazidime-avibactam was approved in patients with hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), based on the multinational Phase 3 REPROVE study. This study assessed efficacy and safety of ceftazidime-avibactam in Chinese adults with HAP/VAP. Metho...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jinyi Yuan, Haihui Huang, Fei Guo, Aimin Li, NanYan Xu, Xiaoyue Chang, Zuke Xiao, Huiqing Zeng, Hua Qiao, Liangfa Tang, Yunsong Yu, Bin Liu, Panpan Wang, Paurus Irani, Rienk Pypstra, Junchao Lu, Fanglei Liu, Yuting Mu, Yingyuan Zhang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-06-01
Edice:	Journal of Global Antimicrobial Resistance
Témata:	Gram-negative bacteria Clinical trial Antimicrobial therapy
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S221371652500061X
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!